About this Journal Submit a Manuscript Table of Contents
Leukemia Research and Treatment
Volume 2011 (2011), Article ID 428960, 4 pages
http://dx.doi.org/10.4061/2011/428960
Review Article

Wnt/ß-Catenin: A New Therapeutic Approach to Acute Myeloid Leukemia

Department of Internal Medicine III, Center for Integrated Oncology (CIO), University of Bonn, Sigmund-Freud-Straße 25, 53105 Bonn, Germany

Received 30 August 2011; Accepted 21 October 2011

Academic Editor: Spiro Konstantinov

Copyright © 2011 Y. Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. G. Gilliland, C. T. Jordan, and C. A. Felix, “The molecular basis of leukemia,” Hematology, pp. 80–97, 2004. View at Scopus
  2. T. Lapidot, C. Sirard, J. Vormoor et al., “A cell initiating human acute myeloid leukaemia after transplantation into SCID mice,” Nature, vol. 367, no. 6464, pp. 645–648, 1994. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. S. W. Lane, Y. J. Wang, C. Lo Celso et al., “Differential niche and Wnt requirements during acute myeloid leukemia progression,” Blood, vol. 118, no. 10, pp. 2849–2856, 2011. View at Publisher · View at Google Scholar · View at PubMed
  4. Y. Okuhashi, M. Itoh, N. Nara, and S. Tohda, “Effects of combination of notch inhibitor plus hedgehog inhibitor or Wnt inhibitor on growth of leukemia cells,” Anticancer Research, vol. 31, no. 3, pp. 893–896, 2011.
  5. A. Gandillet, S. Park, F. Lassailly et al., “Heterogeneous sensitivity of human acute myeloid leukemia to β-catenin down-modulation,” Leukemia, vol. 25, no. 5, pp. 770–780, 2011. View at Publisher · View at Google Scholar · View at PubMed
  6. L. H. Mochmann, J. Bock, J. Ortiz-Tánchez et al., “Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG,” Oncogene, vol. 30, no. 17, pp. 2044–2056, 2011. View at Publisher · View at Google Scholar · View at PubMed
  7. E. K. Siapati, M. Papadaki, Z. Kozaou et al., “Proliferation and bone marrow engraftment of AML blasts is dependent on β-catenin signalling,” The British Journal of Haematology, vol. 152, no. 2, pp. 164–174, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. E. A. Griffiths, S. D. Gore, C. Hooker et al., “Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation,” Leukemia and Lymphoma, vol. 51, no. 9, pp. 1711–1719, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. C. J. Eaves and R. K. Humphries, “Acute myeloid leukemia and the Wnt pathway,” The New England Journal of Medicine, vol. 362, no. 24, pp. 2250–2327, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. Y. Wang, A. V. Krivtsov, A. U. Sinha et al., “The Wnt/β-catenin pathway is required for the development of leukemia stem cells in AML,” Science, vol. 327, no. 5973, pp. 1650–1653, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. M. Schmidt, Y. Kim, S. -M. Gast et al., “Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid,” In Vivo, vol. 25, no. 3, pp. 325–333, 2011.
  12. Y. Kim, G. Reifenberger, D. Lu et al., “Influencing the Wnt signaling pathway in multiple myeloma,” Anticancer Research, vol. 31, no. 2, pp. 725–730, 2011.
  13. K. M. Cadigan and Y. I. Liu, “Wnt signaling: complexity at the surface,” Journal of Cell Science, vol. 119, no. 3, pp. 395–402, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. J. R. Miller, A. M. Hocking, J. D. Brown, and R. T. Moon, “Mechanism and function of signal transduction by the Wnt/B-catenin and Wnt/Ca2+ pathways,” Oncogene, vol. 18, no. 55, pp. 7860–7872, 1999. View at Scopus
  15. Z. You, D. Saims, S. Chen et al., “Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis,” Journal of Cell Biology, vol. 157, no. 3, pp. 429–440, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. Y. Qiang, Y. Endo, J. S. Rubin, and S. Rudikoff, “Wnt signaling in B-cell neoplasia,” Oncogene, vol. 22, no. 10, pp. 1536–1545, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. T. C. Dale, “Signal transduction by the Wnt family of ligands,” Biochemical Journal, vol. 329, no. 2, pp. 209–223, 1998. View at Scopus
  18. X. Q. Gan, J. Y. Wang, Y. Xi, Z. L. Wu, Y. P. Li, and L. Li, “Nuclear Dvl, c-Jun, β-catenin, and TCF form a complex leading to stabilization of β-catenin-TCF interaction,” Journal of Cell Biology, vol. 180, no. 6, pp. 1087–1100, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. S. Amit, A. Hatzubai, Y. Birman et al., “Axin-mediated CKI phosphorylation of β-catenin at Ser 45: a molecular switch for the Wnt pathway,” Genes and Development, vol. 16, no. 9, pp. 1066–1076, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. S. Chen, D. C. Guttridge, Z. You et al., “Wnt-1 signaling inhibits apoptosis by activating β-catenin/T cell factor-mediated transcription,” Journal of Cell Biology, vol. 152, no. 1, pp. 87–96, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Willert, S. Shibamoto, and R. Nusse, “Wnt-induced dephosphorylation of axin releases β-catenin from the axin complex,” Genes and Development, vol. 13, no. 14, pp. 1768–1773, 1999. View at Scopus
  22. A. Kikuchi, S. Kishida, and H. Yamamoto, “Regulation of Wnt signaling by protein-protein interaction and post-translational modifications,” Experimental and Molecular Medicine, vol. 38, no. 1, pp. 1–10, 2006. View at Scopus
  23. P. Polakis, “Wnt signaling and cancer,” Genes and Development, vol. 14, no. 15, pp. 1837–1851, 2000. View at Scopus
  24. D. Lu, Y. Zhao, R. Tawatao et al., “Activation of the Wnt signaling pathway in chronic lymphocytic leukemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 9, pp. 3118–3123, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. U. Steinhusen, V. Badock, A. Bauer et al., “Apoptosis-induced cleavage of β-catenin by caspase-3 results in proteolytic fragments with reduced transactivation potential,” Journal of Biological Chemistry, vol. 275, no. 21, pp. 16345–16353, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. C. M. Edwards, J. R. Edwards, S. T. Lwin et al., “Increasing wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo,” Blood, vol. 111, no. 5, pp. 2833–2842, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. M. Schmidt, E. Sievers, T. Endo, D. Lu, D. Carson, and I. G. H. Schmidt-Wolf, “Targeting Wnt pathway in lymphoma and myeloma cells,” The British Journal of Haematology, vol. 144, no. 5, pp. 796–798, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. T. Oshima, M. Abe, J. Asano et al., “Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2,” Blood, vol. 106, no. 9, pp. 3160–3165, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. J. Dutta-Simmons, Y. Zhang, G. Gorgun et al., “Aurora kinase A is a target of Wnt/β-catenin involved in multiple myeloma disease progression,” Blood, vol. 114, no. 13, pp. 2699–2708, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. Y. W. Qiang, B. Hu, Y. Chen et al., “Bortezomib induces osteoblast differentiation via Wnt-independent activation of β-catenin/TCF signaling,” Blood, vol. 113, no. 18, pp. 4319–4330, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. M. E. Nuttall and J. M. Gimble, “Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications,” Current Opinion in Pharmacology, vol. 4, no. 3, pp. 290–294, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. G. van der Horst, S. M. van der Werf, H. Farih-Sips, R. L. Van Bezooijen, C. W. G. M. Löwik, and M. Karperien, “Downregulation of Wnt signaling by increased expression of Dickkopf-1 and -2 is a prerequisite for late-stage osteoblast differentiation of KS483 cells,” Journal of Bone and Mineral Research, vol. 20, no. 10, pp. 1867–1877, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. D. Zechner, Y. Fujita, J. Hülsken et al., “β-Catenin signals regulate cell growth and the balance between progenitor cell expansion and differentiation in the nervous system,” Developmental Biology, vol. 258, no. 2, pp. 406–418, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. D. A. Glass, P. Bialek, J. D. Ahn et al., “Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation,” Developmental Cell, vol. 8, no. 5, pp. 751–764, 2005. View at Publisher · View at Google Scholar · View at PubMed
  35. J. A. Kennell and O. A. MacDougald, “Wnt signaling inhibits adipogenesis through β-catenin-dependent and -independent mechanisms,” Journal of Biological Chemistry, vol. 280, no. 25, pp. 24004–24010, 2005. View at Publisher · View at Google Scholar · View at PubMed
  36. S. L. Holmen, C. R. Zylstra, A. Mukherjee et al., “Essential role of β-catenin in postnatal bone acquisition,” Journal of Biological Chemistry, vol. 280, no. 22, pp. 21162–21168, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. A. Jackson, B. Vayssiere, T. Garcia et al., “Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells,” Bone, vol. 36, no. 4, pp. 585–598, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. N. Sato, T. Yamabuki, A. Takano et al., “Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy,” Cancer Research, vol. 70, no. 13, pp. 5326–5336, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. S. Aizawa, K. Ookawa, T. Kudo, J. Asano, M. Hayakari, and S. Tsuchida, “Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine,” Cancer Science, vol. 94, no. 10, pp. 886–893, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. R. A. Nagourney, J. C. Messenger, D. H. Kern, and L. M. Weisenthal, “Enhancement of anthracycline and alkylator cytotoxicity by ethacrynic acid in primary cultures of human tissues,” Cancer Chemotherapy and Pharmacology, vol. 26, no. 5, pp. 318–322, 1990. View at Scopus
  41. B. D. Hoffman, H. M. Hanauske-Abel, A. Flint, and M. Lalande, “A new class of reversible cell cycle inhibitors,” Cytometry, vol. 12, no. 1, pp. 26–32, 1991. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. Y. Kim, P. Alpmann, S. Blaum-Feder et al., “Increased In vivo efficacy of lenalidomide by addition of piroctone olamine,” In Vivo, vol. 25, no. 1, pp. 99–103, 2011.
  43. Y. Kim, P. Alpmann, S. Blaum-Feder et al., “In vivo efficacy of griseofulvin against multiple myeloma,” Leukemia Research, vol. 35, no. 8, pp. 1070–1073, 2011. View at Publisher · View at Google Scholar · View at PubMed